Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs

Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Samarin, Jana, Fabrowski, Piotr, Kurilov, Roman, Nuskova, Hana, Hummel-Eisenbeiss, Johanna, Pink, Hannelore, Li, Nan, Weru, Vivienn, Alborzinia, Hamed, Yildiz, Umut, Grob, Laura, Taubert, Minerva, Czech, Marie, Morgen, Michael, Brandstädter, Christina, Becker, Katja, Mao, Lianghao, Jayavelu, Ashok Kumar, Goncalves, Angela, Uhrig, Ulrike, Seiler, Jeanette, Lyu, Yanhong, Diederichs, Sven, Klingmüller, Ursula, Muckenthaler, Martina, Kopp-Schneider, Annette, Teleman, Aurelio, Miller, Aubry K., Gunkel, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053401/
https://www.ncbi.nlm.nih.gov/pubmed/36958250
http://dx.doi.org/10.1016/j.redox.2023.102639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053401/
https://www.ncbi.nlm.nih.gov/pubmed/36958250
http://dx.doi.org/10.1016/j.redox.2023.102639

Ejemplares similares